

**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Attorney Docket No.</b>	59419-010101
<b>First Inventor</b>	NG, Mary Mah Lee
<b>Express Mail Label No.</b>	EV 311274255 US
<b>Title:</b>	MOLECULES, COMPOSITIONS, METHODS AND KITS FOR APPLICATIONS ASSOCIATED WITH FLAVIVIRUSES

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT [37 C.F.R. § 1.56]**

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.


This Information Disclosure Statement is being submitted within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. § 1.53(d), or within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or before the mailing date of a first Office action on the merits, and therefore, Applicant believes no fee is required;

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

No fee is believed due with this submission. However, if Applicants are mistaken, the Commissioner is hereby authorized to charge any required fee in connection with the submission of this paper, or to credit any overpayment to Deposit Account No. 50-2638.

Respectfully submitted,

GREENBERG TRAURIG, LLP



Claude Nassif, Ph.D.

Reg. No. 52,061

Tel.: (310) 586-7828

Date January 22, 2004

**Customer No. 33717**

Greenberg Traurig, LLP  
2450 Colorado Avenue, Suite 400  
Santa Monica, California 90404  
Telephone: 310-586-7700  
Facsimile: 310-586-7800

FORM PTO-1449	Attorney Docket Number	59419-010101
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	Application Number	EV 311274255 US
	Filing Date	January 22, 2004
	Applicant(s)	NG, Mary Mah Lee <i>et al.</i>
	Group Art Unit	To be assigned
	Examiner Name	To be assigned

U.S. PATENT DOCUMENTS						
EXAMINER INITIALS	DOCUMENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIALS	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS	
EXAMINER INITIALS	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Berditchevski <i>et al.</i> ; "Generation of Monoclonal Antibodies to integrin-associated Proteins;" J. Biol. Chem.; Vol. 272, No. 46; Nov 14, 1997; pp. 29174-29180
	Berthet <i>et al.</i> ; "Role of Endoproteolytic Processing in the Adhesive and Signaling Functions of $\alpha_v\beta_3$ Integrin;" J. Biol. Chem.; Vol. 275, No. 43; Oct 27, 2000; pp. 33308-33313
	Borges <i>et al.</i> ; "Platelet-derived Growth Factor Receptor $\beta$ and Vascular Endothelial Growth Factor Receptor 2 Bind to the $\beta_3$ Integrin through Its Extracellular Domain;" J. Biol. Chem.; Vol. 275, No. 51; Dec 22, 2000; pp. 39867-39873
	Chu <i>et al.</i> ; "Characterization of a 105-kDa plasma membrane associated glycoprotein that is involved in West Nile virus binding and infection;" Virology; Vol. 312; 2003; pp. 458-469
	Eigenthaler <i>et al.</i> ; "A Conserved Sequence Motif in the Integrin $\beta_3$ Cytoplasmic Domain Is Required for Its Specific Interaction with $\beta_3$ -Endonexin;" J. Biol. Chem.; Vol. 272, No. 12; Mar 21, 1997; pp. 7693-7698
	Humphries; "Integrin Structure;" Biochemical Society Transactions; Vol. 28, Part 4; 2000; pp. 311-339
	Hynes; "Cell adhesion: old and new questions;" TCB; Vol. 9, No. 12; pp. 0962-8924
	Jenkins <i>et al.</i> ; "Tyrosine Phosphorylation of the $\beta_3$ Cytoplasmic Domain Mediates Integrin-Cytoskeletal Interactions;" J. Biol. Chem.; Vol. 273, No. 22; May 29, 1998; pp. 13878-13885
	Le Naour <i>et al.</i> ; "Severely Reduced Female Fertility in CD9-Deficient Mice;" Science; Vol. 287; Jan 14, 2000; pp. 319-321
	Lin <i>et al.</i> ; "Integrin-mediated Activation of MAP Kinase Is Independent of FAK: Evidence for Dual Integrin Signaling Pathways in Fibroblast;" J. Cell Biol.; Vol. 136, No. 6; Mar 24, 1997; pp. 1385-1395

\\LA-SRV01\217992v01\59419.010101

1

EXAMINER SIGNATURE	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449	Attorney Docket Number	59419-010101
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	Application Number	EV 311274255 US
	Filing Date	January 22, 2004
	Applicant(s)	NG, Mary Mah Lee <i>et al.</i>
	Group Art Unit	To be assigned
	Examiner Name	To be assigned

### U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

### OTHER DOCUMENTS

EXAMINER INITIALS	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Liu <i>et al.</i> ; "Integrin cytoplasmic domain-binding proteins;" J. Cell Sci.; Vol. 113; 2000; pp. 3563-3571
	Porter <i>et al.</i> ; "Integrin take partners: cross-talk between integrins and other membrane receptors;" Cell Biol.; Vol. 8; Oct 1998; pp. 390-396
	Renshaw <i>et al.</i> ; "Growth factor activation of MAP kinase requires cell adhesion;" EMBO J.; Vol. 16, No. 18; 1997; pp. 5592-5599
	Roovers <i>et al.</i> ; "Integrating the MAP kinase signal into the G1 phase cell cycle machinery;" BioEssays; Vol. 22, No. 9; 2000; pp. 818-826
	Schneller <i>et al.</i> ; " $\alpha_3\beta_1$ Integrin associates with activated insulin and PDGF $\beta$ receptors and potentiates the biological activity of PDGF;" Vol. 16, No. 18; 1997; pp. 5600-5607
	Schwartz <i>et al.</i> ; "Interactions between mitogenic stimuli, or, a thousand and one connections;" Curr. Opin. Cell Biol.; Vol. 11; 1999; pp. 197-202
	Skinner <i>et al.</i> ; " $\beta_1$ Integrin Binds the 16-kDa Subunit of Vacuolar H <sup>+</sup> -ATPase at a Site Important for Human Papillomavirus E5 and Platelet-derived Growth Factor Signaling;" J. Biol. Chem.; Vol. 274, No. 33; Aug 13, 1999; pp. 23119-23127
	Timpl; "Macromolecular organization of basement membranes;" Curr. Opin. Cell Biol.; Vol. 8; 1996; pp. 618-624
	Vallar <i>et al.</i> ; "Divalent Cations Differentially Regulate Integrin $\alpha_{1b}$ Cytoplasmic Tail Binding to $\beta_3$ and to Calcium- and Integrin-binding Protein;" J. Biol. Chem; Vol. 274, No. 24; Jun 11, 1999; pp. 17257-17266
	Varner <i>et al.</i> ; "Integrins and cancer;" Curr. Opin. Cell Biol.; Vol. 8; 1996; pp. 724-730

WLA-SRV01\217992v01\59419.010101

2

EXAMINER SIGNATURE	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	